Third Quarter 2015 Earnings Conference Call

November 9, 2015

Aegerion® Pharmaceuticals

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding expectations as to future results, operating expenses, and cash flow; expectations with respect to the impact of PCSK9 inhibitors on the JUXTAPID busine respect to named patient sales outside the U.S and our plans for clinical development, regulatory filings, potential label ex expectations with respect to business development opportunities; expectations with respect to the outcome of ongoing inv status of our existing long-term debt arrangement. These forward-looking statements are neither promises nor guarantee variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materia looking statements. In particular, the risks and uncertainties include, among others: the risk that market acceptance of JU continue at the levels we expect, and may be lower outside the U.S. than we expect; the risk that the conversion of presc on therapy may be lower than we expect or the drop-out rate may be higher than we expect; the risk that the prevalence than our estimates, and that it may be more difficult to identify patients than we expect; the risk that the side effect profile use and in further clinical studies are inconsistent, in scope and severity, with the side effect profile and other results obs that the negative impact of launch of PCSK9 inhibitors on JUXTAPID sales will be greater than we expect, particularly in t greater than we expected to date, or that other competitive products will negatively impact our results; the risk that private our product, or may impose onerous restrictions that hinder reimbursement or significantly limit or cap the price we charg receive our products; the risk that our business may be negatively impacted if there are more Medicaid patients prescribe patient sales in Brazil and other key countries outside the U.S. may not be at the levels we expect; the risk that regulatory products is not yet approved may not be satisfied with the efficacy or safety profile of the product; the risk that we do not countries on a timely basis, or at all, or that regulatory authorities impose significant restrictions on approval or require ad rates will negatively impact the amount of net product sales recognized; the risk that technical hurdles may delay initiation be successful in our label expansion or business development efforts; the risk that our patent portfolio and marketing and anticipate; the risk of unexpected manufacturing issues affecting future supply; the risk of an enforcement action or settle probable result of the ongoing DOJ and SEC investigations, and the terms thereof, with respect to ongoing or future inves unpredictable nature and timing of government investigations, and the impact of investigations on our business; the risk th responding to investigations and defending ourselves in litigation and in connection with any settlement entered into in co Silicon Valley Bank will accelerate our long-term debt as a result of our breach of certain covenants of our agreement with foregoing may cause product sales revenue to be lower than we expect, or that we may incur unanticipated expenses in c inherent in the commercialization, drug development and regulatory approval process.

For additional disclosure regarding these and other risks we face, see the disclosure contained in the "Risk Factors" secti filed on November 9, 2015, and our other public filings with the Securities and Exchange Commission, available on the S undertake no obligation to update or revise the information contained in this press release, whether as a result of new info otherwise.

Unless otherwise noted, persons shown throughout this presentation are models used for illustrative purposes and are not patients.

Executing on Key Business Objectives

- **US COMMERCIAL OPERATIONS:** Growing MYALEPT patient
  evolving JUXTAPID market dynamics
- **EU MARKET ACCESS:** Pricing and reimbursement approval for
- **LIFE CYCLE MANAGEMENT/BUSINESS DEVELOPMENT:** Pri
  strategic plan

Building a Global Orphan Drug Company

Commercial Product Portfolio

Juxtapid (lomitapide) capsules

myalept (metreleptin) for injection 11.3mg per vial

Pipeline

MYALE

JUXTAP

*subject

JUXTAPID: U.S. Metrics

Cumulative Dropout
from launch through 10/30/15

Two factors contributing to +9% increase:
- Switches to PCSK9 inhibitor
- JUXTAPID discontinuation

Date	% Increase	Rate
10/30/15	**+9%**	**58%**
7/31/15	+3%	49%
4/24/15	+5%	46%
12/31/14	+5%	41%
9/30/14	+5%	36%

Cumulative Dropout: Total # of patients who have discontinued therapy from date of launch in January 2013, as a % of all patients who have received at least one shipment.

Compliance
launch – 10/30/15

- Steady

80-90%

MYALEPT: U.S. Metrics

Active Commercial GL Patients on Therapy
as of 10/30/15

78

+10 patients since 7/31/15

Cumulative Dropout
mid-2014 – 10/30/15

8%

Cumulative Dropout: Total # of patients who have discontinued therapy from date of launch in mid-2014, as a % of all patients who have received at least one shipment.

Compliance
Launch through 10/30/15

80-90%

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.